Qrons Stock Price, News & Analysis

QRON OTC

Company Description

QRons Inc., a preclinical stage biotechnology company, focuses on developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, particularly traumatic brain injuries. The company's product candidates include QS100, an injury-specific, 3D printable, implantable modified mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries. QRons Inc. has a license and research funding agreement with Ariel University R&D Co., Ltd. for the development and commercialization of products for neuronal tissue regeneration and repair.

Formerly known as Biolabmart Inc., QRons Inc. changed its name in August 2017. The company, founded in 2016, is based in New York, New York.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

- %

Performance 1 year

$2.9M

Market Cap

17.9M

Shares outstanding

Latest News

View All

November 20, 2023

0.00%

Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program

management

August 23, 2023

0.00%

Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis

August 14, 2023

0.00%

Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis

July 25, 2023

0.00%

Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and TBIs

July 20, 2023

32.12%

Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries

March 22, 2023

0.00%

Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels

SEC Filings

View All

No SEC filings available for Qrons.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Qrons (QRON)?

The current stock price of Qrons (QRON) is $0.15 as of March 31, 2025.

What is the market cap of Qrons (QRON)?

The market cap of Qrons (QRON) is approximately 2.9M.

What is QRons Inc.'s focus?

QRons Inc. primarily focuses on developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, specifically traumatic brain injuries.

What are the product candidates of QRons Inc.?

QRons Inc.'s product candidates include QS100, an implantable modified mesenchymal stem cells (MSCs)-synthetic hydrogel for penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel for diffused injuries.

Who does QRons Inc. have a licensing agreement with?

QRons Inc. has a license and research funding agreement with Ariel University R&D Co., Ltd. for the development and commercialization of products for neuronal tissue regeneration and repair.

When was QRons Inc. founded?

QRons Inc. was founded in 2016.

Where is QRons Inc. based?

QRons Inc. is based in New York, New York.

What is the history behind QRons Inc.'s name change?

Formerly known as Biolabmart Inc., QRons Inc. changed its name to QRons Inc. in August 2017.